Investigating the quality of marketed Azithromycin in the Democratic Republic of the Congo: A case of tablets in the city of Kisangani

Introduction Azithromycin is an antibiotic belonging to the macrolide family. It is widely used in the management of infectious diseases caused by both Gram-positive and Gram-negative bacteria, as well as certain aerobic infections. During the COVID-19 outbreak, its use increased in many countries as part of disease management protocols. Unfortunately, this surge was associated with the introduction of counterfeit products on the market. This drug remains widely circulated, particularly in the far north of Kisangani Province in the Democratic Republic of the Congo. Purpose This study aimed to evaluate the quality of marketed Azithromycin tablets available in the region of Kisangani, Democratic Republic of the Congo. Methods To achieve this goal, appropriate physicochemical analyses were conducted to verify product quality through organoleptic, pharmaco-technical, qualitative, and quantitative assessments. A total of 14 samples from seven different laboratories (two batches from each) were collected. The study adopted a cross-sectional laboratory-based design using UV-Vis spectrophotometry and HPLC techniques. Data were statistically analysed using the Student’s t-test method. Results Analyses yielded satisfactory results for 100% of the samples, which were consistent with survey findings and confirmed the effectiveness and reliability of Azithromycin-based treatment, except for one sample (Zithromcin, batches 1 and 2) that failed the friability test. This non-conforming result represented less than 20% of the total sample size. Conclusion The study results align with those obtained from the survey. We recommend that regulatory authorities use similar analytical tests and trials for drug approval processes and the classification of high-monitoring drugs. The analytical methods implemented in this research can serve as reference procedures for routine quality control of this macrolide antibiotic.

Institutions

Publication Details

Journal
SHILAP Revista de lepidopterología
Published
2025-10-01
DOI
https://doi.org/10.4314/orapj.v6i10.93
Primary Topic
Pharmaceutical Quality and Counterfeiting
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Investigating the quality of marketed Azithromycin in the Democratic Republic of the Congo: A case of tablets in the city of Kisangani

SHILAP Revista de lepidopterología
Pharmaceutical Quality and Counterfeiting
article

Investigating the quality of marketed Azithromycin in the Democratic Republic of the Congo: A case of tablets in the city of Kisangani

article en

Abstract

Introduction Azithromycin is an antibiotic belonging to the macrolide family. It is widely used in the management of infectious diseases caused by both Gram-positive and Gram-negative bacteria, as well as certain aerobic infections. During the COVID-19 outbreak, its use increased in many countries as part of disease management protocols. Unfortunately, this surge was associated with the introduction of counterfeit products on the market. This drug remains widely circulated, particularly in the far north of Kisangani Province in the Democratic Republic of the Congo. Purpose This study aimed to evaluate the quality of marketed Azithromycin tablets available in the region of Kisangani, Democratic Republic of the Congo. Methods To achieve this goal, appropriate physicochemical analyses were conducted to verify product quality through organoleptic, pharmaco-technical, qualitative, and quantitative assessments. A total of 14 samples from seven different laboratories (two batches from each) were collected. The study adopted a cross-sectional laboratory-based design using UV-Vis spectrophotometry and HPLC techniques. Data were statistically analysed using the Student’s t-test method. Results Analyses yielded satisfactory results for 100% of the samples, which were consistent with survey findings and confirmed the effectiveness and reliability of Azithromycin-based treatment, except for one sample (Zithromcin, batches 1 and 2) that failed the friability test. This non-conforming result represented less than 20% of the total sample size. Conclusion The study results align with those obtained from the survey. We recommend that regulatory authorities use similar analytical tests and trials for drug approval processes and the classification of high-monitoring drugs. The analytical methods implemented in this research can serve as reference procedures for routine quality control of this macrolide antibiotic.

SHILAP Revista de lepidopterología
University of Kinshasa (CD), National Institute of Biomedical Research (CD), Université de Kisangani (CD)
Openalex Percentile: Top 35%
Pharmaceutical Quality and Counterfeiting
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Investigating the quality of marketed Azithromycin in the Democratic Republic of the Congo: A case of tablets in the city of Kisangani · SHILAP Revista de lepidopterología (2025) | TGRS Research Map | TGRS